Last reviewed · How we verify

CD1579 5% — Competitive Intelligence Brief

CD1579 5% (CD1579 5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: retinoid. Area: Dermatology.

phase 2 retinoid retinoic acid receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

CD1579 5% (CD1579 5%) — Galderma R&D. CD1579 5% is a topical retinoid that modulates cell growth and differentiation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CD1579 5% TARGET CD1579 5% Galderma R&D phase 2 retinoid retinoic acid receptor
Sohonos PALOVAROTENE Ipsen marketed Retinoid [EPC] Retinoic acid receptor gamma 2023-01-01
Targretin BEXAROTENE Bausch Health marketed Retinoid [EPC] Retinoic acid receptor RXR-beta 1999-01-01
Panretin ALITRETINOIN Advanz marketed Retinoid [EPC] Retinoic acid receptor beta 1999-01-01
Differin ADAPALENE Galderma Labs Lp marketed Retinoid [EPC] Retinoic acid receptor beta 1996-01-01
Tegison ETRETINATE marketed Retinoid Retinoic acid receptor RXR-gamma 1986-01-01
Accutane ISOTRETINOIN marketed Retinoid [EPC] Retinoic acid receptor alpha 1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (retinoid class)

  1. Galderma R&D · 2 drugs in this class
  2. Encube Ethicals Pvt. Ltd. · 1 drug in this class
  3. Fougera Pharmaceuticals Inc. · 1 drug in this class
  4. Kowa Company, Ltd. · 1 drug in this class
  5. South Plains Oncology Consortium · 1 drug in this class
  6. Stiefel, a GSK Company · 1 drug in this class
  7. Actavis Inc. · 1 drug in this class
  8. Teva Pharmaceuticals USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CD1579 5% — Competitive Intelligence Brief. https://druglandscape.com/ci/cd1579-5. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: